Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.
This new designation aims to benefit HS-20093's development as a treatment for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, which has progressed or recurred following platinum-based chemotherapy.
HS-20093 was previously granted BTDs for extensive-stage small-cell lung cancer that developed after standard first-line treatment and for osteosarcoma in patients with disease progression after at least two prior lines of therapy, according to a Thursday filing with the Hong Kong Exchange.
Drug candidates with BTD status gain advantages like potential conditional approval and priority review, accelerating their development for serious diseases with limited treatment options.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。